Anesth Pain Med.  2020 Jan;15(1):28-34. 10.17085/apm.2020.15.1.28.

Comparison of palonosetron and ondansetron to prevent postoperative nausea and vomiting in women using intravenous patient-controlled analgesia

• Yoo JH
• Jeon IS
• Chung JW
• Ryoo JH
• You GW
• Kim SI

• KMID: 2500451
• DOI: http://doi.org/10.17085/apm.2020.15.1.28

Abstract

Background
We compared the effects of palonosetron with ondansetron for preventing postoperative nausea and vomiting (PONV) during the first 24 h after surgery in women receiving intravenous patient-controlled analgesia (IV-PCA) with fentanyl for pain control.
Methods
In this prospective, randomized, double-blinded study, 204 healthy patients who were undergoing elective surgery with general anesthesia were enrolled. In the palonosetron group (n = 102), 0.075 mg bolus was given intravenously (i.v.) 30 min before the end of surgery and 8 ml saline was added to the IV-PCA. In the ondansetron group (n = 102), 8 mg bolus i.v. was given 30 min before the end of surgery and 16 mg of ondansetron was added to the IV-PCA. The incidence of PONV, severity of nausea, and use of rescue anti-emetics were evaluated 6 and 24 h after the operation.
Results
The incidences of nausea (55.6%) and vomiting (14.1%) in the palonosetron group did not differ from those (58.3 and 19.8%) in the ondansetron group during the first 24 h after surgery (P > 0.05). No significant differences were observed in the severity of nausea and use of rescue anti-emetics between the two groups (P > 0.05).
Conclusions
The effects of palonosetron in preventing PONV were not different from those of ondansetron during the first 24 h postoperatively in women receiving IV-PCA with fentanyl.

Keyword

Ondansetron; Palonosetron; Postoperative nausea and vomiting

Figure

• 

  Fig. 1 CONSORT diagram. CONSORT: consolidated standards of reporting trials.

Reference

Kovac AL. 2013. Update on the management of postoperative nausea and vomiting. Drugs. 73:1525–47. DOI: 10.1007/s40265-013-0110-7. PMID: 24057415.

Gan TJ., Diemunsch P., Habib AS., Kovac A., Kranke P., Meyer TA, et al. 2014. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 118:85–113. DOI: 10.1213/ANE.0000000000000002. PMID: 24356162.

Rojas C., Stathis M., Thomas AG., Massuda EB., Alt J., Zhang J, et al. 2008. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 107:469–78. DOI: 10.1213/ane.0b013e318172fa74. PMID: 18633025.

Gralla R., Lichinitser M., Van Der Vegt S S., Sleeboom H., Mezger J., Peschel C, et al. 2003. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 14:1570–7. DOI: 10.1093/annonc/mdg417. PMID: 14504060.

Kovac AL., Eberhart L., Kotarski J., Clerici G., Apfel C. 2008. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 107:439–44. DOI: 10.1213/ane.0b013e31817abcd3. PMID: 18633021.

Ho KY., Gan TJ. 2006. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 19:606–11. DOI: 10.1097/01.aco.0000247340.61815.38. PMID: 17093363.

Kim SI., Kim SC., Baek YH., Ok SY., Kim SH. 2009. Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery. Br J Anaesth. 103:549–53. DOI: 10.1093/bja/aep209. PMID: 19700442.

AbdEl-Hamid AM., Othman MSK., Afifi EE. 2014. Palonosetron versus ondansetron for prevention of postoperative nausea and vomiting during middle ear surgery: a double-blind, randomized, comparative trial. Ain-Shams J Anesthesiol. 7:309–13.

Bajwa SS., Bajwa SK., Kaur J., Sharma V., Singh A., Singh A, et al. 2011. Palonosetron: a novel approach to control postoperative nausea and vomiting in day care surgery. Saudi J Anaesth. 5:19–24. DOI: 10.4103/1658-354X.76484. PMID: 21655011. PMCID: PMC3101747.

Bhalla J., Baduni N., Bansal P. 2015. Comparison of palanosetron with ondansetron for postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy under general anesthesia. J Minim Access Surg. 11:193–7. DOI: 10.4103/0972-9941.140219. PMID: 26195878. PMCID: PMC4499925.

Joshi H., Parmar P., Raval B. 2014. Comparison of ondansetron v/s palonosetron for prevention of post-operative nausea and vomiting in laparoscopic surgery. Res J Pharm Biol Chem Sci. 5:54–63.

Kim SH., Hong JY., Kim WO., Kil HK., Karm MH., Hwang JH. 2013. Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study. Korean J Anesthesiol. 64:517–23. DOI: 10.4097/kjae.2013.64.6.517. PMID: 23814652. PMCID: PMC3695249.

Park SK., Cho EJ. 2011. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery. J Int Med Res. 39:399–407. DOI: 10.1177/147323001103900207. PMID: 21672343.

Shadangi BK., Agrawal J., Pandey R., Kumar A., Jain S., Mittal R, et al. 2013. A prospective, randomized, double-blind, comparative study of the efficacy of intravenous ondansetron and palonosetron for prevention of postoperative nausea and vomiting. Anaesth Pain Intensive Care. 17:55–8.

Sharma AN., Shankaranarayana P. 2015. Postoperative nausea and vomiting: palonosetron with dexamethasone vs. ondansetron with dexamethasone in laparoscopic hysterectomies. Oman Med J. 30:252–6. DOI: 10.5001/omj.2015.51. PMID: 26366258. PMCID: PMC4561637.

Moon YE., Joo J., Kim JE., Lee Y. 2012. Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study. Br J Anaesth. 108:417–22. DOI: 10.1093/bja/aer423. PMID: 22277663.

Kim YY., Moon SY., Song DU., Lee KH., Song JW., Kwon YE. 2013. Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery. Korean J Anesthesiol. 64:122–6. DOI: 10.4097/kjae.2013.64.2.122. PMID: 23459499. PMCID: PMC3581780.

Watcha MF., White PF. 1992. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 77:162–84. DOI: 10.1097/00000542-199207000-00023. PMID: 1609990.

Wong EH., Clark R., Leung E., Loury D., Bonhaus DW., Jakeman L, et al. 1995. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 114:851–9. DOI: 10.1111/j.1476-5381.1995.tb13282.x. PMID: 7773546. PMCID: PMC1510197.

Stoltz R., Cyong JC., Shah A., Parisi S. 2004. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U. S. and Japanese healthy subjects. J Clin Pharmacol. 44:520–31. DOI: 10.1177/0091270004264641. PMID: 15102873.

Aapro MS., Grunberg SM., Manikhas GM., Olivares G., Suarez T., Tjulandin SA, et al. 2006. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 17:1441–9. DOI: 10.1093/annonc/mdl137. PMID: 16766588.

Siddiqui MA., Scott LJ. 2004. Palonosetron. Drugs. 64:1125–32. discussion 1133-4. DOI: 10.2165/00003495-200464100-00006. PMID: 15139789.

Candiotti KA., Kovac AL., Melson TI., Clerici G., Joo Gan T; Palonosetron 04-06 Study Group Group. 2008. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. 107:445–51. DOI: 10.1213/ane.0b013e31817b5ebb. PMID: 18633022.

Tramèr MR., Reynolds DJ., Moore RA., McQuay HJ. 1997. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. 87:1277–89. DOI: 10.1097/00000542-199712000-00004. PMID: 9416710.

Apfel CC., Korttila K., Abdalla M., Kerger H., Turan A., Vedder I, et al. 2004. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 350:2441–51. DOI: 10.1056/NEJMoa032196. PMID: 15190136. PMCID: PMC1307533.

Choi DK., Chin JH., Lee EH., Lim OB., Chung CH., Ro YJ, et al. 2010. Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery. Acta Anaesthesiol Scand. 54:962–9. DOI: 10.1111/j.1399-6576.2010.02275.x. PMID: 20626355.

Chun HR., Jeon IS., Park SY., Lee SJ., Kang SH., Kim SI. 2014. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth. 112:485–90. DOI: 10.1093/bja/aet340. PMID: 24154700.

Tramèr MR. 2001. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand. 45:4–13. DOI: 10.1034/j.1399-6576.2001.450102.x. PMID: 11152031.

Apfel CC., Roewer N., Korttila K. 2002. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand. 46:921–8. DOI: 10.1034/j.1399-6576.2002.460801.x. PMID: 12190791.

Morganroth J., Flaharty KK., Parisi S., Moresino C. 2016. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer. 24:621–7. DOI: 10.1007/s00520-015-2822-6. PMID: 26111957. PMCID: PMC4689761.